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Ro 46-2005 is a new synthetic non-peptide endothelin (ET) receptor antagonist. In binding experiments, Ro 46-2005 proved to be equipotent (ICs0 
200-500 nM) for inhibition of [~25I]ET-1 binding on the two known ET receptor subtypes (ETA and ETB). Scatchard analysis was consistent with 
a competitive binding mode. Ro 46-2005 also inhibited the functional consequences of ET-1 stimulation: the ET-l-induced release of arachidonic 
acid from rat mesangial cells was inhibited with an IC50 of 1.8/.LM. 
Endothelin: Endothelin antagonist; Endothelin receptor; Arachidonic acid release 
1. INTRODUCTION 
Endothelin (ET), a 21 amino acid peptide, containing 
two disulfide bridges, is the most potent vasoconstrictor 
known to date [1]. It has been detected in man in the 
form of three different isopeptides, named ET-1, ET-2 
and ET-3 [2]. Increased ET levels have been described 
in diseases accompanied by vasoconstriction r inflam- 
mation, e.g. subarachnoidal hemorrhage [3,4], conges- 
tive heart failure [5,6], angina pectoris [7], ulcerative 
colitis [8] and renal failure [9]. Additionally, ET might 
play a key role in chronic diseases like atherosclerosis 
[10] and hypertension [11]. Two G-protein-coupled ET
receptors with seven transmembrane spanning domains 
have been described, cloned from human tissue and 
defined as ETA [12] and ETB receptors [13]. Whereas 
ETA receptors are selective for ET-t and ET-2 over 
ET-3, ET~ receptors bind all three isopeptides with sim- 
ilar potency. ET A receptors, mainly located on smooth 
muscle cells, were originally thought o be responsible 
for vasoconstriction, while ETB receptors, located on 
endothelial cells, were believed to mediate vasodilation. 
However, ETB receptors which mediate vasoconstric- 
tion have recently also been described [14,15]. This new 
receptor subtype is not blocked by the peptidic ET A 
selective antagonists, BQ 123 [16] and FR 139317 [17]. 
The role of the ET receptor subtypes in the pathology 
of the above mentioned diseases is unknown. However, 
taking into account hat both ET A and ETB receptors 
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may be involved in vasoconstriction it might be an ad- 
vantage to block both receptor subtypes with an unse- 
lective receptor antagonist. Our goal was to study 
whether Ro 46-2005, anovel non-peptide ET antagonist 
[18], would fulfill this requirement. We therefore per- 
formed competition and saturation binding studies on 
tissues or cells containing either ETA or ETB receptors. 
Moreover, we analyzed the effect of Ro 46-2005 on the 
release of arachidonic acid, one of the second messen- 
gers involved in the action of ET [19,20]. 
2. MATERIALS AND METHODS 
2.1. Materials 
[~25I]ET-1, [12SI]ET-2 and [1251]ET-3 were obtained from Anawa 
(Wangen, Switzerland). ET-1, ET-2, ET-3 were purchased from Nova- 
biochem AG (L/iufelfingen, Switzerland). [3H]Arachidonic acid 
[5,6,8,9,11,12,14,15] was from Amersham (Rahn AG, Zt~rich, Switzer- 
land). Phosphoramidon was obtained from Sigma, Bio-Science Prod- 
ucts AG (Emmenbriicke, Switzerland). Human placentas were ob- 
tained from a local maternity hospital and porcine cerebellum was 
obtained from the local slaughter house. All tissues were stored at 
-80°C. Culture reagents were from Gibco Laboratories (Paisley, Scot- 
land, UK). 
2.2. Cell culture 
Rat aortic endothelial cells, rat mesangial cells, human smooth 
muscle cells and baculovirus-infected insect cells (Sf9 cells) were cul- 
tured as described previously [21-23]. 
2.3. Preparation of membranes 
Microsomal membranes from human placenta or porcine cerebel- 
lum were prepared as described earlier [24]. Briefly, the tissue was 
homogenized in 5 mM Tris buffer, pH 7.4, containing 1mM MgC12 
and 250 mM sucrose with a polytron (Kinematica Ltd., Switzerland) 
and subsequently with a potter homogenizer (Vetter Ltd., Germany). 
After centrifugation at 3,000 x g for 15 rain at 4°C, the supernatant 
was centrifuged again at 72,000 x g for 40 min. The resulting pellet was 
finally suspended in 2.5 ml 75 mM Tris buffer (pH 7.4) containing 25 
mM MgC12 and 250 mM sucrose. Baculovirus infected insect cells 
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expressing either recombinant ET a or recombinant ETB receptor 
cloned from human placenta [25,26] were broken by three freeze/ 
thawing cycles in hypotonic Tris buffer (5 raM, pH 7.4, 1 mM MgCIz), 
homogenized and centrifuged at 72,000 x g for 15 min. The pellet was 
washed twice with 75 mM Tris buffer, pH 7.4, containing 25 mM 
MgCI2 and 250 mM sucrose, resuspended in the same buffer and 
stored in aliquots at -80°C. 
Protein was determined according to the method of Lowry [27] 
using bovine serum albumin (BSA) as a standard. 
2.4. Binding assays 
2.4.1. Competition binding 
Competition binding assays were performed either on membrane 
preparations (human placenta, porcine cerebellum, baculovirus-in- 
fected insect cells) or on whole attached cells (rat mesangial cells, 
human smooth muscle cells, rat endothelial cells). 
Binding assays on membranes were performed in 250/11 50 mM Tris 
buffer (pH 7.4, 25 mM MnC12, 1 mM EDTA, 0.5% (w/v) BSA) con- 
taining 5-35 ¢tg protein, 32 pM ~25I-labelled ET and increasing 
amounts of unlabelled ligands. In binding assays with [~251]ET-3 on 
ET A receptor a tracer concentration f 213 pM was used. After incu- 
bation for 2 h at 22°C, bound and free ligand were separated by 
filtration. 
Binding assays with whole attached cells were performed in 500 pl 
Dulbecco's modified Eagle's medium (DMEM) containing 2 mg/ml 
BSA and 25 mM HEPES. After incubation (2 h, 22°C) in the presence 
of 35 pM [12SI]ET-1 and increasing concentrations of Ro 46-2005, the 
cells were extensively washed and finally solubilized in 1% (w/v) SDS, 
0.5 M NaOH, 100 mM EDTA. 
Each assay was performed three times in triplicate and non-specific 
binding was assessed in the presence of 100 nM unlabelled ET-1. 
Specific binding was defined as the difference between total binding 
and non specific binding. IC50 values were determined after logit/log 
transformation f the binding data. 
2.4.2. Saturation binding 
Saturation binding experiments were performed either with mem- 
branes of baculovirus-infected insect cells carrying recombinant 
human ETa receptor, (5 ,ug protein/well), or with membranes from 
human placenta (35 rug protein/well), containing mainly ETB recep- 
tors. The membranes were incubated for 3 h with increasing amounts 
of radiolabelled [J25I]ET-1 (6.4-660 pM) in the presence of varying 
concentrations of Ro 46-2005. The assays were performed in triplicate 
and non-specific binding was assessed in the presence of 100 nM 
unlabelled ET-1. K D and Bm,~ values were calculated by linear regres- 
sion analysis of Scatchard plots. 
2.5. Measurement of arachidonic acid release 
[3H]Arachidonic acid release was measured by a modification of the 
method of Felder et al. [28]. Confluent rat mesangial cells grown in 
24 well plates (400,000 cells/well) were incubated for 24 h with [3H]- 
arachidonic acid (1 pCi/well), washed three times with DMEM supple- 
mented with 2 mg/ml bovine serum albumin, 25 mM HEPES, pH 7.4, 
and incubated in this medium for 30 rain at 37°C. After an additional 
washing step the reaction was started by replacing the buffer with fresh 
medium containing varying amounts of ET-1 and Ro 46-2005. All 
incubation and washing steps were performed both in the presence and 
in the absence of phosphorarnidon (100 pM). After incubation (0-30 
min), the supernatant from each well was removed and centrifuged (10 
min, 1,100 rpm) to sediment detached cells. Finally, [3H]arachidonic 
acid release into the incubation medium was quantified by liquid 
scintillation counting. Three experiments were performed in triplicate. 
Data are presented as mean + S.E.M. 
3. RESULTS 
Ro 46-2005 competed for the binding of [~5I]ET-1 on 
cells carrying ETA receptor, i.e. human smooth muscle 
cells and rat mesangial cells, with ICs0 values of 
220 + 60 nM and 430 + 140 nM, respectively (Fig. 1A). 
Its potency for binding to ETB receptors was similar on 
membranes of human placenta (ICs0 160 + 77 nM) and 
porcine cerebellum (ICs0 227 + 92 nM), but differed on 
rat endothelial cells (IC50 1,140 + 340 nM) (Fig. 1B). 
We could demonstrate that human placental mem- 
branes contain > 90% ET B receptors (data not shown). 
To assess the potency of Ro 46-2005 on pure receptor 
subtypes, we used recombinant ETA (recETA) and ETB 
(recETB) receptors. These recombinant receptors 
showed the characteristic pattern of potency for ET-1 
and ET-3, recETA receptor being selective for ET-1 
(IC50 0.290 + 0.075 nM) compared to ET-3 (IC50 150 
+ 70 riM) and recETB receptor being about equipotent 
for ET-1 (IC50 0.44 + 0.28 nM) and ET-3 (IC50 0.11 
+ 0.01 nM). The ETA-selective peptide antagonists, BQ 
123 [16] and FR 139317 [17], potently competed for 
[~25I] ET-1 binding to the recETA receptor with IC50 
values of 63 + 16 nM and 13 _+ 4 nM, respectively. 
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Fig. 2. Competition binding curves with different ~25I-labelled ET peptides, [~25I]ET-1 (32 pM, E), [t2SI]ET-2 (32 pM, $), [125I]ET-3 (213 pM, A) 
and unlabelled Ro 46-2005. Values are means of three independent experiments. (A) Recombinant ET A receptor. (B) Human placenta (_> 90% ETB; 
< 10% ETA). 
However, neither ligand competed for [~25I]ET-1 bind- 
ing on the recETB receptor up to a concentration f 100 
/IM. In contrast, the ETB-selective ligand, sarafotoxin 
$6c [29], did not bind to the recETA receptor, but had 
a potency of 0.120 + 0.01 nM on the recETB receptor. 
Ro 46-2005 displayed a potency (IC50) of 360 _ 160 nM 
on recETA receptors (Fig. 1A) and 530 _+ 150 nM on 
recET B receptors (Fig. 1B). 
Furthermore, Ro 46-2005 competed with a similar 
potency for binding of [125I]ET-1, [125I]ET-2 and 
[125I]ET-3 on recET A (Fig. 2A), resulting in IC50 values 
of 360 + 160 nM, 397_+ 53 and 212 + 45 nM and on 
natural ETB receptors (human placenta, Fig. 2B) giving 
IC50 values of 160 _+ 77, 97 _ 5 and 113 _+ 4 nM. 
Saturation binding experiments were performed with 
the same receptor preparations u ing [125I]ET-1 and var- 
ying concentrations of Ro 46-2005. On recETA recep- 
tors, the apparent KD values for ET-1 increased in the 
presence of increasing concentrations of Ro 46-2005: 
68 pM (control), 163 pM (0.65 ktM Ro 46-2005), 198 
pM (1.3 pM Ro 46-2005) and 477 pM (2.5 /tM Ro 
46-2005), the corresponding values for Bmax remained 
unchanged at3,000 + 150 fmol/mg protein (Fig. 3A). A 
similar result was obtained with placental membranes 
(90% ETB receptors) (Fig. 3B). In the presence Of 0 nM 
(control), 0.1, 0.2 and 0.4 ,uM Ro 46-2005, the corre- 
sponding KD values for ET-1 were 20, 29, 57 and 82 pM, 
respectively. Again, the apparent number of binding 
sites remained constant at 138 + 7 fmol/mg. Thus, Ro 
46-2005 displays acompetitive mode of binding to both 
receptor subtypes. 
We further analyzed whether the binding of Ro 46- 
2005 to the ET receptors was translated into a similar 
potency for inhibition of signal transduction. ET-1 in- 
duced a dose-dependent release of arachidonic acid 
from rat mesangial cells with an ECs0 value of 4.4 nM. 
The maximal stimulation of arachidonic acid release 
was 870 + 40% above baseline with 330 nM ET-1. This 
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Fig. 4. Inhibition of the ET-l-mediated release of arachidonic acid by 
rat mesangial cells in the presence of Ro 46-2005. Represented is the 
mean + S.E.M. of three independent experiments. 
response could be increased to 1,400 + 60% when all 
incubation steps were performed in the presence of 0.1 
mM phosphoramidon. The ECs0 value for ET-1 re- 
mained unchanged under these conditions. The ET-t 
(10 nM)-stimulated release of arachidonic acid in- 
creased rapidly with time during the first 10 min and 
reached aplateau after about 30 min. In order to obtain 
a maximal response we thus performed our experiments 
with 10 nM ET-1 and an incubation time of 30 min in 
the presence of 0.1 mM phosphoramidon. Under these 
conditions Ro 46-2005 dose-dependently inhibited the 
release of arachidonic acid with an ICs0 of 1.8 + 0.3 ¢tM 
(Fig. 4). 
4. DISCUSSION 
Endothelin (ET) mediates its effects via at least two 
different receptor subtypes, ET A and ET B. To inhibit its 
actions, it might be necessary to block these and possi- 
bly further existing receptor subtypes imultaneously. 
Ro 46-2005, a recently described synthetic non-peptide 
ET antagonist [18], was shown to prevent he cerebral 
vasoconstriction which follows subarachnoidal hemor- 
rhage and the post-ischemic renal vasoconstriction in 
rats. In competition binding studies with [125I]ET-1, 
[125I]ET-2 and [~25I]ET-3, Ro 46-2005 is characterized by
its non-selective interaction with ET A and ET B recep- 
tors. It binds to natural ETA receptors containing tissue, 
i.e. human smooth muscle cells and rat mesangial cells, 
and also to recombinant human ET A receptors with 
similar potencies. Comparable potencies are also ob- 
served for its binding to membranes containing natural 
ETa receptors, i.e. porcine cerebellum and human pla- 
centa, and also for recombinant ETB receptors. These 
data show that Ro 46-2005 exhibits little if any species- 
specific differences, uggesting that its binding sites are 
highly conserved. The observed potency of Ro 46-2005 
to compete for [~2SI]ET-1 binding on ETB containing rat 
endothelial cells is about 5-fold lower than on mem- 
branes containing natural ET B receptors. This may be 
due to different binding and buffer conditions. 
Our results derived from saturation binding experi- 
ments in the presence of different concentrations of Ro 
46-2005' indicate a competitive binding mode on both 
receptor subtypes. This conclusion confirms the obser- 
vation that Ro 46-2005 induces parallel shifts to the 
right of the concentration-response curves for ETA and 
ETB receptors in isolated vessels without decrease in 
maximal response [18]. 
Another important question was whether the potency 
observed in these binding studies was translated into a 
similar potency for inhibition of signal transduction. 
The ET-l-mediated activation of phospholipase A2, 
which leads to the release of arachidonic acid and its 
derivatives, has been described for different cells, like 
vascular smooth muscle cells [19], rat mesangial cells 
[20] and mouse astrocytes [30]. Our experiments were 
performed in the presence of phosphoramidon, an in- 
hibitor of the ET-converting enzyme which cleaves ET 
from its precursor, big ET [31], This results in an in- 
crease in the ET- 1-mediated release of arachidonic acid 
by rat mesangial cells of 1.6 fold. We have recently 
shown that ET-converting enzyme inhibition by 
phosphoramidon can prevent desensitization f recep- 
tors by endogenously formed ET and increase the num- 
ber of available sites, thereby increasing the maximal 
response to ET-1 without affecting its potency [21]. The 
potency of Ro 46-2005 for inhibiting arachidonic acid 
release is comparable to the potency found in binding 
studies, which confirms the receptor antagonistic effect 
of Ro 46-2005. 
In summary, Ro 46-2005 is a competitive ET antago- 
nist for both ET A and ETB receptors which should pro- 
vide a useful tool to get further insight into the physio- 
logical actions of endothelins. 
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